Damon Runyon will invest up to $3.6 million over three years to recruit the most talented young scientists to become the next leaders in computational biology.

In September, first- and third-year Damon Runyon Fellows came together from their separate labs around the country at the Annual Fellows’ Retreat. Held in Southbridge, Massachusetts this year, the Fellows took the opportunity to network, share ideas and get professional advice from leaders in all fields of cancer research.

William G. Kaelin, Jr, MD, of Dana-Farber Cancer Institute and Harvard Medical School, shares the Nobel Prize in Physiology or Medicine for discoveries of how cells sense and adapt to oxygen availability.

Peter J. Turnbaugh, PhD (Damon Runyon Innovator '16-'20), at the University of California, San Francisco, discusses his recent discovery that eating a diet of cooked food fundementally changes the microbes living in the gut compared to a diet of raw foods.

Surprising new research from Jason M. Sheltzer, PhD (Damon Runyon-Rachleff Innovator ’18 - ’20) and colleagues at Cold Spring Harbor Laboratory suggests why 97% of cancer drugs in clinical trials fail to stop cancer in patients and never make it to market.

Yung S. Lie, PhD, President and CEO of Damon Runyon Cancer Research Foundation, sat down with Denver Frederick, host of “The Business of Giving” on AM 970 The Answer WNYM in New York City, to discuss the history and strategy of the organization.  

Two Damon Runyon alumni have been awarded the 2019 Lasker Awards, which “honor innovations that have advanced knowledge, treatment, or prevention of disease,” and are considered to be one of the highest international honors in medical research. H. Michael Shepard, PhD (Damon Runyon Fellow ’78-’80), shares the prize for his contribution to the discovery of the breast cancer treatment Herceptin. Jacques F.A.P. Miller, PhD (Damon Runyon Grantee ’73-’75), shares the award for pioneering immunology research that has led to many new therapeutic approaches. 

For the ninth year in a row, Damon Runyon has earned a 4-star rating from Charity Navigator for “demonstrating strong financial health and commitment to accountability and transparency.” 

The warnings to use sunscreen are very real -- skin is the largest organ of the body and the most vulnerable to DNA damage caused by the sun’s ultraviolet rays. Basal cell carcinoma (BCC), a form of skin cancer, is the most common cancer in the United States with 3 million cases diagnosed annually. These cancers tend to grow slowly, usually developing on sun-exposed areas such as the head and neck, and treatment involves surgically removing the tumor. Usually this doesn’t present complications, but some individuals develop frequent recurrences of BCC that require multiple painful surgeries and scars.  

CAR (chimeric antigen receptor) T cell immunotherapy has generated much excitement in the last two years— saving the lives of some blood cancer patients when other treatments have failed. Developing CAR T therapies for solid tumors has been far more challenging. That could be changing. Marcela V. Maus, MD, PhD (Damon Runyon-Rachleff Innovator ’17-’20), and colleagues at Massachusetts General Hospital have turned CAR T cells into virtual armored vehicles, capable of launching deadly strikes against glioblastoma brain tumors.